Avadel Pharmaceuticals Reports 54.9% Revenue Growth to $77.5 Million in Latest Quarter

Avadel Pharmaceuticals plc reported significant financial improvements in its latest quarterly results, with net product revenue reaching $77.5 million for the three months ended September 30, 2025, a 54.9% increase from $50.0 million in the same period last year. For the nine months ended September 30, 2025, revenue totaled $198.1 million, up 66.9% from $118.7 million in the prior year. The company achieved a gross profit of $81.6 million for the third quarter, compared to $43.9 million a year earlier, reflecting a gross profit margin of 105%. This increase in revenue and profit is attributed to the successful launch and growing adoption of LUMRYZ, an extended-release formulation of sodium oxybate for treating narcolepsy.

Operating expenses also rose significantly, totaling $79.6 million for the third quarter, up from $44.2 million in the same period last year. This increase was driven primarily by higher research and development costs, which surged to $27.0 million from $3.8 million, largely due to a $20.0 million upfront payment related to a licensing agreement with XWPharma for the development of valiloxybate. Selling, general, and administrative expenses also increased, reflecting the costs associated with the commercialization of LUMRYZ. Despite these rising costs, Avadel reported an operating income of $1.9 million for the third quarter, a turnaround from an operating loss of $327,000 in the same quarter of 2024.

In terms of operational metrics, the number of patients treated with LUMRYZ increased to approximately 3,400 as of September 30, 2025, compared to about 2,300 a year earlier. This growth in patient count is indicative of the product's market acceptance and the effectiveness of the company's marketing strategies. The company also noted a decrease in the cost of products sold, which fell significantly due to a reversal of estimated royalties previously recorded, following a settlement agreement with Jazz Pharmaceuticals.

Looking ahead, Avadel has entered into a transaction agreement with Alkermes plc, under which Alkermes will acquire Avadel. The transaction is expected to close in the first quarter of 2026, subject to shareholder approval and regulatory clearances. The agreement includes a cash consideration of $18.50 per share, along with potential additional payments based on performance milestones. This acquisition is anticipated to provide Avadel with additional resources to further develop its product pipeline and enhance its market position.

Overall, Avadel's financial performance reflects a positive trajectory, driven by the successful commercialization of LUMRYZ and strategic partnerships aimed at expanding its product offerings. The company remains focused on navigating the competitive landscape of the biopharmaceutical industry while managing its operational costs and pursuing growth opportunities.